A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD

Trial Profile

A Two Part, Double Blind, Placebo Controlled, Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Doses of QBM076 in Patients With COPD

Discontinued
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2016

At a glance

  • Drugs QBM 076 (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 Mar 2016 No of arms changed from 10 to 6 as per ClinicalTrials.gov record.
    • 29 Sep 2015 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top